Tumor antigen positive cell lines were subsequently targeted by CAR NK cells (GTA102) to investigate the efficiency of antigen-specific targeting of resistant tumor cells. It is essential to evaluate the potency of cell-based immunotherapy products in both 2D and 3D settings to target solid tumors efficiently. Most importantly, our results demonstrate that introduction of CAR to NK cells significantly improves targeting of UCB-NK cell resistant antigen+ CRC cells and stands out as a potential cell therapy product for the treatment of colorectal cancer patients.